823 related articles for article (PubMed ID: 27696296)
61. Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma.
Zhou L; Husted H; Moore T; Lu M; Deng D; Liu Y; Ramachandran V; Arumugam T; Niehrs C; Wang H; Chiao P; Ling J; Curran MA; Maitra A; Hung MC; Lee JE; Logsdon CD; Hwang RF
Sci Transl Med; 2018 Oct; 10(464):. PubMed ID: 30355799
[TBL] [Abstract][Full Text] [Related]
62. BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling.
Liu X; Tian X; Wang F; Ma Y; Kornmann M; Yang Y
Eur J Cancer; 2014 Sep; 50(13):2251-62. PubMed ID: 24953335
[TBL] [Abstract][Full Text] [Related]
63.
Tadros S; Shukla SK; King RJ; Gunda V; Vernucci E; Abrego J; Chaika NV; Yu F; Lazenby AJ; Berim L; Grem J; Sasson AR; Singh PK
Cancer Res; 2017 Oct; 77(20):5503-5517. PubMed ID: 28811332
[TBL] [Abstract][Full Text] [Related]
64. BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine.
Miller AL; Fehling SC; Vance RB; Chen D; Brown EJ; Hossain MI; Heard EO; Andrabi SA; Wang H; Yang ES; Buchsbaum DJ; van Waardenburg RCAM; Bellis SL; Yoon KJ
Cancer Lett; 2024 Jun; 592():216919. PubMed ID: 38704133
[TBL] [Abstract][Full Text] [Related]
65. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment.
Liu Q; Wu H; Li Y; Zhang R; Kleeff J; Zhang X; Cui M; Liu J; Li T; Gao J; Pan B; Wu W; Wang W; Zhou L; Guo J; Dai M; Zhang T; Liao Q; Lu Z; Zhao Y
Cancer Immunol Immunother; 2020 Aug; 69(8):1477-1492. PubMed ID: 32285172
[TBL] [Abstract][Full Text] [Related]
66. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.
Zhuang Z; Li H; Lee H; Aguilar M; Gocho T; Ju H; Iida T; Ling J; Fu J; Wu M; Sun Y; Lu Y; Chiao PJ
Cancer Lett; 2017 Dec; 411():44-56. PubMed ID: 28951128
[TBL] [Abstract][Full Text] [Related]
67. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
Skrypek N; Vasseur R; Vincent A; Duchêne B; Van Seuningen I; Jonckheere N
Oncotarget; 2015 May; 6(13):10853-67. PubMed ID: 25890497
[TBL] [Abstract][Full Text] [Related]
68. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.
Adesso L; Calabretta S; Barbagallo F; Capurso G; Pilozzi E; Geremia R; Delle Fave G; Sette C
Oncogene; 2013 Jun; 32(23):2848-57. PubMed ID: 22797067
[TBL] [Abstract][Full Text] [Related]
69. MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2.
An Y; Cai B; Chen J; Lv N; Yao J; Xue X; Tu M; Tang D; Wei J; Jiang K; Wu J; Li Q; Gao W; Miao Y
Cancer Lett; 2013 Feb; 329(2):228-35. PubMed ID: 23178452
[TBL] [Abstract][Full Text] [Related]
70. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma.
Park JK; Kim Y; Kim H; Jeon J; Kim TW; Park JH; Hwnag YI; Lee WJ; Kang JS
Oncotarget; 2016 Nov; 7(46):75081-75093. PubMed ID: 27655706
[TBL] [Abstract][Full Text] [Related]
71. Quantification of fluorophore distribution and therapeutic response in matched in vivo and ex vivo pancreatic cancer model systems.
Solanki A; King D; Thibault G; Wang L; Gibbs SL
PLoS One; 2020; 15(2):e0229407. PubMed ID: 32097436
[TBL] [Abstract][Full Text] [Related]
72. Prolactin receptor potentiates chemotherapy through miRNAs-induced G6PD/TKT inhibition in pancreatic cancer.
Liao YN; Huang PQ; Pan H; Gai YZ; Zhan YF; Li SX; Nie HZ
FASEB J; 2024 May; 38(10):e23705. PubMed ID: 38805171
[TBL] [Abstract][Full Text] [Related]
73. ASO Author Reflections: Regulation of Chemoresistance in Pancreatic Ductal Adenocarcinoma by Scavenger Receptor CD36.
Kubo M; Eguchi H
Ann Surg Oncol; 2020 Feb; 27(2):620-621. PubMed ID: 31659646
[No Abstract] [Full Text] [Related]
74. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals.
Miyabayashi K; Ijichi H; Mohri D; Tada M; Yamamoto K; Asaoka Y; Ikenoue T; Tateishi K; Nakai Y; Isayama H; Morishita Y; Omata M; Moses HL; Koike K
Cancer Res; 2013 Apr; 73(7):2221-34. PubMed ID: 23378339
[TBL] [Abstract][Full Text] [Related]
75. HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1.
Lu Y; Xu D; Peng J; Luo Z; Chen C; Chen Y; Chen H; Zheng M; Yin P; Wang Z
EBioMedicine; 2019 Jun; 44():403-418. PubMed ID: 31103629
[TBL] [Abstract][Full Text] [Related]
76. TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC.
Huang W; Hu X; He X; Pan D; Huang Z; Gu Z; Huang G; Wang P; Cui C; Fan Y
Drug Resist Updat; 2024 May; 74():101079. PubMed ID: 38518727
[TBL] [Abstract][Full Text] [Related]
77. Role of pancreatic stellate cells and periostin in pancreatic cancer progression.
Liu Y; Du L
Tumour Biol; 2015 May; 36(5):3171-7. PubMed ID: 25840689
[TBL] [Abstract][Full Text] [Related]
78. Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma.
Gonzalez-Villasana V; Rodriguez-Aguayo C; Arumugam T; Cruz-Monserrate Z; Fuentes-Mattei E; Deng D; Hwang RF; Wang H; Ivan C; Garza RJ; Cohen E; Gao H; Armaiz-Pena GN; Del C Monroig-Bosque P; Philip B; Rashed MH; Aslan B; Erdogan MA; Gutierrez-Puente Y; Ozpolat B; Reuben JM; Sood AK; Logsdon C; Lopez-Berestein G
Mol Cancer Ther; 2014 Nov; 13(11):2583-94. PubMed ID: 25193509
[TBL] [Abstract][Full Text] [Related]
79. A Stromal Lysolipid-Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression.
Auciello FR; Bulusu V; Oon C; Tait-Mulder J; Berry M; Bhattacharyya S; Tumanov S; Allen-Petersen BL; Link J; Kendsersky ND; Vringer E; Schug M; Novo D; Hwang RF; Evans RM; Nixon C; Dorrell C; Morton JP; Norman JC; Sears RC; Kamphorst JJ; Sherman MH
Cancer Discov; 2019 May; 9(5):617-627. PubMed ID: 30837243
[TBL] [Abstract][Full Text] [Related]
80. RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma.
Tu Q; Liu X; Yao X; Li R; Liu G; Jiang H; Li K; Chen Q; Huang X; Chang Q; Xu G; Zhu H; Shi P; Zhao B
J Exp Clin Cancer Res; 2022 Sep; 41(1):274. PubMed ID: 36109793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
